ClinicalTrials.gg
Status unknownNCT04351932Updated Apr 17, 2020

Bone Marrow Versus Adipose Autologous Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis

A Phase 3 interventional study of bone marrow mesenchymal stem cells and Adipose Mesenchymal stem cells in Osteo Arthritis Knee, sponsored by Universidad Catolica Santiago de Guayaquil. Status unknown at 1 site in Ecuador. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-04-17.

Sponsored by Universidad Catolica Santiago de Guayaquil · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2020), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Phase 3
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Mesenchymal stem cells (MSC) are stromal cells that have the ability to self-renew and also exhibit multilineage differentiation. MSCs can be isolated from a variety of tissues, such as umbilical cord, bone marrow, and adipose tissue. The multipotent properties of MSCs make them a promising option for the treatment of osteoarthritis (OA).

Bone marrow mesenchymal stem cells (BM-MSC) and adipose derived mesenchymal stem cells (AD-MSC) have been used separately to treat OA. The aim of the present study will be to compare in a randomized non blind controlled clinical trial 3 types of intra-articular injections containing MSC populations obtained from two clinically relevant sources: BM-MSC, AD-MSC and a combination of both BM-MSC and AD-MSC.

Read the detailed description

The aim of the present study will be to compare 3 types of intra-articular injections of MSC populations obtained from two clinically relevant sources: injections containing BM-MSC or AD-MSC or a combination of both BM-MSC,and AD-MSC in a randomized non blind clinical trial.

To assess the efficacy and safety of 3 kind of MSC injections in relation to pain, function and quality of life in patients with knee OA.

A total of 54 patients with the diagnosis of knee OA grade II and III will be recruited to receive a single intra-articular injection of MSC: Group 1 (n 18 patients) will receive BM-MSC, Group 3 (n 18 patients) will receive AD-MSC. Group 3 (18 patients) will receive a combination of BM-MSC and AD-MSC.

A randomized non blind clinical trial with active control. For this purpose, the random number generator is 54, found on the RANDOM.ORG ® website (available at https://www.random.org/integers/)

02

Conditions studied

  • Osteo Arthritis Knee

Keywords

  • Mesenchymal stem cell
03

In context

Lead sponsor

Universidad Catolica Santiago de Guayaquil is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 to 70 years, with grade II and III knee OA, according to the Ahlbäck classification will be included.
  • Minimal VAS pain score of 4.
  • Chronic knee pain of mechanical origin.
  • All patients who sign a specially prepared for this clinical trial.

Exclusion criteria

Exclusion Criteria:

  • Varus or valgus knee mal alignment superior to 10°.
  • OA grade IV according Ahlbäck classification.
  • Bone marrow cancer like lymphoma.
  • Severe anemia.
  • Active infections.
  • Pregnant patients.
  • Inmune diseases such as Rheumatoid arthritis, gout or pseudogout arthritis, psoriasis.
  • Bone diseases such as Kahler and Paget.
  • Corticoesteroid and hyaluronic injections within the last 3 months.
  • Knee surgery in the last 6 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Active comparator
    bone marrow mesenchymal stem cell

    Bone marrow mesenchymal stem cells 10 cc by intra articular injection once

    Biological: bone marrow mesenchymal stem cells

  • Active comparator
    adipose mesenchymal stem cells

    Stromal vascular factor from adipose mesenchymal stem cells 10 cc by intra articular injection once

    Biological: Adipose Mesenchymal stem cells

  • Active comparator
    Bone marrow and Adipose mesenchymal stem cells

    Bone marrow and Stromal vascular factor from adipose mesenchymal stem cells 5 cc each one, by intra articular injection once.

    Biological: bone marrow & adipose mesenchymal stem cells injection

Interventions

  • Biologicalbone marrow mesenchymal stem cells

    intrarticular bone marrow mesenchymal stem cells injection

  • BiologicalAdipose Mesenchymal stem cells

    intrarticular adipose mesenchymal stem cells injection

  • Biologicalbone marrow & adipose mesenchymal stem cells injection

    intrarticular bone marrow and adipose stem cells injection.

06

What researchers measure

Primary outcomes

  1. knee pain assessed by Visual Analogue Scale.

    psychometric response scale which used in questionnaires. It is a measurement instrument for subjective characteristics of pain . Score from O to 10. O indicate no pain, and 10 indicate the worst pain.

    Time frame: 12 months

  2. knee function assessed by WOMAC (Wester Ontario McMaster Osteoarthritis Index). quosteionary.

    The Index contains 24 questions five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68). Individual question responses are assigned a score of between 0 (extreme) and 4 (None). Individual question scores are then summed to form a raw score ranging from 0 (worst) to 96 (best). Finally, raw scores are normalized by multiplying each score by 100/96. This produces a reported WOMAC Score of between 0 (worst) to 100 (best).

    Time frame: 12 months

Secondary outcomes

  1. Quantitative T2-Mapping Evaluation of Changes in Cartilage Matrix

    MRI T2 mapping of the cartilage is a non-invasive functional imaging technique delivering cartography of the T2 relaxation time of the cartilage without any contrast injection. It is sensitive to tissue anisotropy, and provides compositional information on the cartilage collagen network, water content and proteoglycans concentration.

    Time frame: 6 months after procedure

07

Study locations

1 site
08

References and documents

Publications

  • Wagner W, Wein F, Seckinger A, Frankhauser M, Wirkner U, Krause U, Blake J, Schwager C, Eckstein V, Ansorge W, Ho AD. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol. 2005 Nov;33(11):1402-16. doi: 10.1016/j.exphem.2005.07.003. PubMed 16263424 ↗
  • Wakitani S, Imoto K, Yamamoto T, Saito M, Murata N, Yoneda M. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. Osteoarthritis Cartilage. 2002 Mar;10(3):199-206. doi: 10.1053/joca.2001.0504. PubMed 11869080 ↗
  • Xia P, Wang X, Lin Q, Li X. Efficacy of mesenchymal stem cells injection for the management of knee osteoarthritis: a systematic review and meta-analysis. Int Orthop. 2015 Dec;39(12):2363-72. doi: 10.1007/s00264-015-2785-8. Epub 2015 May 6. PubMed 25944079 ↗
  • Wakitani S, Okabe T, Horibe S, Mitsuoka T, Saito M, Koyama T, Nawata M, Tensho K, Kato H, Uematsu K, Kuroda R, Kurosaka M, Yoshiya S, Hattori K, Ohgushi H. Safety of autologous bone marrow-derived mesenchymal stem cell transplantation for cartilage repair in 41 patients with 45 joints followed for up to 11 years and 5 months. J Tissue Eng Regen Med. 2011 Feb;5(2):146-50. doi: 10.1002/term.299. PubMed 20603892 ↗
  • Jo CH, Lee YG, Shin WH, Kim H, Chai JW, Jeong EC, Kim JE, Shim H, Shin JS, Shin IS, Ra JC, Oh S, Yoon KS. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial. Stem Cells. 2014 May;32(5):1254-66. doi: 10.1002/stem.1634. Erratum In: Stem Cells. 2017 Jun;35(6):1651-1652. doi: 10.1002/stem.2589. PubMed 24449146 ↗
  • Peeters CM, Leijs MJ, Reijman M, van Osch GJ, Bos PK. Safety of intra-articular cell-therapy with culture-expanded stem cells in humans: a systematic literature review. Osteoarthritis Cartilage. 2013 Oct;21(10):1465-73. doi: 10.1016/j.joca.2013.06.025. Epub 2013 Jul 4. PubMed 23831631 ↗
  • Freitag J, Bates D, Boyd R, Shah K, Barnard A, Huguenin L, Tenen A. Mesenchymal stem cell therapy in the treatment of osteoarthritis: reparative pathways, safety and efficacy - a review. BMC Musculoskelet Disord. 2016 May 26;17:230. doi: 10.1186/s12891-016-1085-9. PubMed 27229856 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — all IPD that underlie results in a publication

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: JUNE 2021 TO SEPTEMBER 2021

Access criteria: drcarloschiriboga@gmail.com

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04351932
Lead sponsor
Universidad Catolica Santiago de Guayaquil
Responsible party
Dr. Carlos Chiriboga Accini (Research Professor. Orthopaedic Staff. Omnihospital., Universidad Catolica Santiago de Guayaquil) — Principal investigator
First posted
Apr 17, 2020
Start date
Jun 7, 2020 (estimated)
Primary completion
Jun 7, 2021 (estimated)
Completion
Sep 7, 2021 (estimated)
Last update
Apr 17, 2020

Study contacts

Carlos A Chiriboga, MD
Contact
drcarloschiriboga@gmail.com
593 9 9995 4148
Peter A Chedraui, Phd
Contact
peter.chedraui@cu.ucsg.edu.ec
593 9 9942 4629
Carlos A Chiriboga, MD
principal investigator · Universidad Católica Santiago de Guayaquil

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion